{"disease":{"id":"severe-aplastic-anemia","name":"severe aplastic anemia"},"drugs":{"marketed":[{"drug_id":"eltrombopag","indication_name":"Severe Aplastic Anemia (First-Line)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"eltrombopag","indication_name":"Severe Aplastic Anemia (Second-Line)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05012111","title":"Natural History of Acquired and Inherited Bone Marrow Failure Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03825744","title":"Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01623167","title":"Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT04436380","title":"Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06069180","title":"The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04961710","title":"Extension Study of Hetrombopag in Severe Aplastic Anemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05998408","title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":145,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT01174108","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT00001964","title":"Combination Therapy of Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06964971","title":"Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"The First Affiliated Hospital of Zhejiang Chinese Medical University","has_results":false},{"nct_id":"NCT02979873","title":"Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04304820","title":"Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT05433922","title":"Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05797623","title":"Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT00061360","title":"Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06695741","title":"Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06517641","title":"Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT03246178","title":"Haploidentical Transplantation in Severe Aplastic Anemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Wu Xiaoxiong","has_results":false},{"nct_id":"NCT06412497","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03520647","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03557099","title":"A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT02998645","title":"Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05660785","title":"Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05720234","title":"Avatrombopag Combined With IST as First-line Treatment for SAA","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03579875","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT00195624","title":"Alemtuzumab to Treat Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT05531279","title":"A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency","phase":"NA","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05975996","title":"Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07297550","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT01891994","title":"Extended Dosing With Eltrombopag for Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT07299123","title":"Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04436367","title":"Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03173937","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04328727","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03192397","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01768845","title":"Unrelated Umbilical Cord Blood (UBC)Transplantation","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"West Virginia University","has_results":true},{"nct_id":"NCT00001626","title":"Comparing Therapies for the Treatment of Severe Aplastic Anemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT02918292","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT00604201","title":"Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT06378060","title":"Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hematology department of the 920th hospital","has_results":false},{"nct_id":"NCT01900119","title":"A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT04099966","title":"AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Mitchell Cairo","has_results":false},{"nct_id":"NCT02828592","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Northside Hospital, Inc.","has_results":false},{"nct_id":"NCT06254560","title":"Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03836690","title":"Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04356469","title":"TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":17,"lead_sponsor_name":"Johns Hopkins All Children's Hospital","has_results":false},{"nct_id":"NCT04409080","title":"REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06622694","title":"CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT00358657","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}